Loading…

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

Sixty‐six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin‐D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessmen...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1978-07, Vol.42 (1), p.19-22
Main Authors: Schein, Philip S., Lavin, Philip T., Moertel, Charles G., Frytak, Stephen, Hahn, Richard G., O'Connell, Michael J., Reitemeier, Richard J., Rubin, Joseph, Schutt, Allen J., Weiland, Louis H., Kalser, M., Barkin, J., Lessner, H., Mann‐Kaplan, R., Redlhammer, D., Silverman, M., Troner, M., Douglass, H. O., Milliron, S., Lokich, J., Brooks, J., Chaffe, J., Like, A., Zamcheck, N., Ramming, K., Bateman, J., Spiro, H., Livstone, E., Knowlton, A.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 22
container_issue 1
container_start_page 19
container_title Cancer
container_volume 42
creator Schein, Philip S.
Lavin, Philip T.
Moertel, Charles G.
Frytak, Stephen
Hahn, Richard G.
O'Connell, Michael J.
Reitemeier, Richard J.
Rubin, Joseph
Schutt, Allen J.
Weiland, Louis H.
Kalser, M.
Barkin, J.
Lessner, H.
Mann‐Kaplan, R.
Redlhammer, D.
Silverman, M.
Troner, M.
Douglass, H. O.
Milliron, S.
Lokich, J.
Brooks, J.
Chaffe, J.
Like, A.
Zamcheck, N.
Ramming, K.
Bateman, J.
Spiro, H.
Livstone, E.
Knowlton, A.
description Sixty‐six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin‐D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin‐D responded. The duration of responses ranged from 43–64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin‐D therapy.
doi_str_mv 10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4
format article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmed_primary_352505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR2820420103</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2113-df587f2ee9521878ce2eab253b06b7d654eb43c803fd7d9bf29e72906cb56eeb3</originalsourceid><addsrcrecordid>eNpdUdtu1DAUtBC3pfAHPPgRpGY5tpNNsiDQKrSwUsVKFUi8Wb6ctEa5yXFol6d-Ah_CV_VLcFhUCV7s8RnNWGeGkHcMlgyAv2JQ5gmwlL9gZV5A_jLla_aGlev1Zvs-qT5V57zgkHJgIN6KJSyr3WuepPfI4k55nywAoEiyVHx9TJ6M47f4zHkmHpGHIuMZZAvy61x1tm_dD7R0uFQj0u2WmsZ1zqiGBu_i2ddU2YjavXHdMW0xXPbB47UKeEyjnCoTXNf_oW9vflrquij4rjoTTVtU4-SVbpAOceJRBWeoUd7MErWkG3qhxuB71wUco8_87dT2no5hsnt64ftpoB6H3oen5EGtmhGf_b2PyJfTk8_Vx-Rs92Fbbc6SgTMmEltnRV5zxDLjrMgLgxyVjntrWOncrrIUdSpMAaK2uS11zUvMeQkro7MVohZH5PnBd5h0i1YO3rXK7-UhtEjrA33lGtzfsQzk3Jyc85dz_vLQnJxRxDIWJ_8tTgoJstpJLtP_GPEbVRuYCg</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report</title><source>EZB Electronic Journals Library</source><creator>Schein, Philip S. ; Lavin, Philip T. ; Moertel, Charles G. ; Frytak, Stephen ; Hahn, Richard G. ; O'Connell, Michael J. ; Reitemeier, Richard J. ; Rubin, Joseph ; Schutt, Allen J. ; Weiland, Louis H. ; Kalser, M. ; Barkin, J. ; Lessner, H. ; Mann‐Kaplan, R. ; Redlhammer, D. ; Silverman, M. ; Troner, M. ; Douglass, H. O. ; Milliron, S. ; Lokich, J. ; Brooks, J. ; Chaffe, J. ; Like, A. ; Zamcheck, N. ; Ramming, K. ; Bateman, J. ; Spiro, H. ; Livstone, E. ; Knowlton, A.</creator><creatorcontrib>Schein, Philip S. ; Lavin, Philip T. ; Moertel, Charles G. ; Frytak, Stephen ; Hahn, Richard G. ; O'Connell, Michael J. ; Reitemeier, Richard J. ; Rubin, Joseph ; Schutt, Allen J. ; Weiland, Louis H. ; Kalser, M. ; Barkin, J. ; Lessner, H. ; Mann‐Kaplan, R. ; Redlhammer, D. ; Silverman, M. ; Troner, M. ; Douglass, H. O. ; Milliron, S. ; Lokich, J. ; Brooks, J. ; Chaffe, J. ; Like, A. ; Zamcheck, N. ; Ramming, K. ; Bateman, J. ; Spiro, H. ; Livstone, E. ; Knowlton, A.</creatorcontrib><description>Sixty‐six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin‐D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin‐D responded. The duration of responses ranged from 43–64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin‐D therapy.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(197807)42:1&lt;19::AID-CNCR2820420103&gt;3.0.CO;2-4</identifier><identifier>PMID: 352505</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Bone Marrow - drug effects ; Clinical Trials as Topic ; Dactinomycin - adverse effects ; Dactinomycin - therapeutic use ; Doxorubicin - adverse effects ; Doxorubicin - therapeutic use ; Drug Evaluation ; Female ; Humans ; Male ; Methotrexate - adverse effects ; Methotrexate - therapeutic use ; Middle Aged ; Pancreatic Neoplasms - drug therapy ; Remission, Spontaneous ; Time Factors</subject><ispartof>Cancer, 1978-07, Vol.42 (1), p.19-22</ispartof><rights>Copyright © 1978 American Cancer Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/352505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schein, Philip S.</creatorcontrib><creatorcontrib>Lavin, Philip T.</creatorcontrib><creatorcontrib>Moertel, Charles G.</creatorcontrib><creatorcontrib>Frytak, Stephen</creatorcontrib><creatorcontrib>Hahn, Richard G.</creatorcontrib><creatorcontrib>O'Connell, Michael J.</creatorcontrib><creatorcontrib>Reitemeier, Richard J.</creatorcontrib><creatorcontrib>Rubin, Joseph</creatorcontrib><creatorcontrib>Schutt, Allen J.</creatorcontrib><creatorcontrib>Weiland, Louis H.</creatorcontrib><creatorcontrib>Kalser, M.</creatorcontrib><creatorcontrib>Barkin, J.</creatorcontrib><creatorcontrib>Lessner, H.</creatorcontrib><creatorcontrib>Mann‐Kaplan, R.</creatorcontrib><creatorcontrib>Redlhammer, D.</creatorcontrib><creatorcontrib>Silverman, M.</creatorcontrib><creatorcontrib>Troner, M.</creatorcontrib><creatorcontrib>Douglass, H. O.</creatorcontrib><creatorcontrib>Milliron, S.</creatorcontrib><creatorcontrib>Lokich, J.</creatorcontrib><creatorcontrib>Brooks, J.</creatorcontrib><creatorcontrib>Chaffe, J.</creatorcontrib><creatorcontrib>Like, A.</creatorcontrib><creatorcontrib>Zamcheck, N.</creatorcontrib><creatorcontrib>Ramming, K.</creatorcontrib><creatorcontrib>Bateman, J.</creatorcontrib><creatorcontrib>Spiro, H.</creatorcontrib><creatorcontrib>Livstone, E.</creatorcontrib><creatorcontrib>Knowlton, A.</creatorcontrib><title>Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Sixty‐six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin‐D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin‐D responded. The duration of responses ranged from 43–64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin‐D therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Bone Marrow - drug effects</subject><subject>Clinical Trials as Topic</subject><subject>Dactinomycin - adverse effects</subject><subject>Dactinomycin - therapeutic use</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Methotrexate - adverse effects</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Remission, Spontaneous</subject><subject>Time Factors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><recordid>eNpdUdtu1DAUtBC3pfAHPPgRpGY5tpNNsiDQKrSwUsVKFUi8Wb6ctEa5yXFol6d-Ah_CV_VLcFhUCV7s8RnNWGeGkHcMlgyAv2JQ5gmwlL9gZV5A_jLla_aGlev1Zvs-qT5V57zgkHJgIN6KJSyr3WuepPfI4k55nywAoEiyVHx9TJ6M47f4zHkmHpGHIuMZZAvy61x1tm_dD7R0uFQj0u2WmsZ1zqiGBu_i2ddU2YjavXHdMW0xXPbB47UKeEyjnCoTXNf_oW9vflrquij4rjoTTVtU4-SVbpAOceJRBWeoUd7MErWkG3qhxuB71wUco8_87dT2no5hsnt64ftpoB6H3oen5EGtmhGf_b2PyJfTk8_Vx-Rs92Fbbc6SgTMmEltnRV5zxDLjrMgLgxyVjntrWOncrrIUdSpMAaK2uS11zUvMeQkro7MVohZH5PnBd5h0i1YO3rXK7-UhtEjrA33lGtzfsQzk3Jyc85dz_vLQnJxRxDIWJ_8tTgoJstpJLtP_GPEbVRuYCg</recordid><startdate>197807</startdate><enddate>197807</enddate><creator>Schein, Philip S.</creator><creator>Lavin, Philip T.</creator><creator>Moertel, Charles G.</creator><creator>Frytak, Stephen</creator><creator>Hahn, Richard G.</creator><creator>O'Connell, Michael J.</creator><creator>Reitemeier, Richard J.</creator><creator>Rubin, Joseph</creator><creator>Schutt, Allen J.</creator><creator>Weiland, Louis H.</creator><creator>Kalser, M.</creator><creator>Barkin, J.</creator><creator>Lessner, H.</creator><creator>Mann‐Kaplan, R.</creator><creator>Redlhammer, D.</creator><creator>Silverman, M.</creator><creator>Troner, M.</creator><creator>Douglass, H. O.</creator><creator>Milliron, S.</creator><creator>Lokich, J.</creator><creator>Brooks, J.</creator><creator>Chaffe, J.</creator><creator>Like, A.</creator><creator>Zamcheck, N.</creator><creator>Ramming, K.</creator><creator>Bateman, J.</creator><creator>Spiro, H.</creator><creator>Livstone, E.</creator><creator>Knowlton, A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>197807</creationdate><title>Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report</title><author>Schein, Philip S. ; Lavin, Philip T. ; Moertel, Charles G. ; Frytak, Stephen ; Hahn, Richard G. ; O'Connell, Michael J. ; Reitemeier, Richard J. ; Rubin, Joseph ; Schutt, Allen J. ; Weiland, Louis H. ; Kalser, M. ; Barkin, J. ; Lessner, H. ; Mann‐Kaplan, R. ; Redlhammer, D. ; Silverman, M. ; Troner, M. ; Douglass, H. O. ; Milliron, S. ; Lokich, J. ; Brooks, J. ; Chaffe, J. ; Like, A. ; Zamcheck, N. ; Ramming, K. ; Bateman, J. ; Spiro, H. ; Livstone, E. ; Knowlton, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2113-df587f2ee9521878ce2eab253b06b7d654eb43c803fd7d9bf29e72906cb56eeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Bone Marrow - drug effects</topic><topic>Clinical Trials as Topic</topic><topic>Dactinomycin - adverse effects</topic><topic>Dactinomycin - therapeutic use</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Methotrexate - adverse effects</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Remission, Spontaneous</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schein, Philip S.</creatorcontrib><creatorcontrib>Lavin, Philip T.</creatorcontrib><creatorcontrib>Moertel, Charles G.</creatorcontrib><creatorcontrib>Frytak, Stephen</creatorcontrib><creatorcontrib>Hahn, Richard G.</creatorcontrib><creatorcontrib>O'Connell, Michael J.</creatorcontrib><creatorcontrib>Reitemeier, Richard J.</creatorcontrib><creatorcontrib>Rubin, Joseph</creatorcontrib><creatorcontrib>Schutt, Allen J.</creatorcontrib><creatorcontrib>Weiland, Louis H.</creatorcontrib><creatorcontrib>Kalser, M.</creatorcontrib><creatorcontrib>Barkin, J.</creatorcontrib><creatorcontrib>Lessner, H.</creatorcontrib><creatorcontrib>Mann‐Kaplan, R.</creatorcontrib><creatorcontrib>Redlhammer, D.</creatorcontrib><creatorcontrib>Silverman, M.</creatorcontrib><creatorcontrib>Troner, M.</creatorcontrib><creatorcontrib>Douglass, H. O.</creatorcontrib><creatorcontrib>Milliron, S.</creatorcontrib><creatorcontrib>Lokich, J.</creatorcontrib><creatorcontrib>Brooks, J.</creatorcontrib><creatorcontrib>Chaffe, J.</creatorcontrib><creatorcontrib>Like, A.</creatorcontrib><creatorcontrib>Zamcheck, N.</creatorcontrib><creatorcontrib>Ramming, K.</creatorcontrib><creatorcontrib>Bateman, J.</creatorcontrib><creatorcontrib>Spiro, H.</creatorcontrib><creatorcontrib>Livstone, E.</creatorcontrib><creatorcontrib>Knowlton, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schein, Philip S.</au><au>Lavin, Philip T.</au><au>Moertel, Charles G.</au><au>Frytak, Stephen</au><au>Hahn, Richard G.</au><au>O'Connell, Michael J.</au><au>Reitemeier, Richard J.</au><au>Rubin, Joseph</au><au>Schutt, Allen J.</au><au>Weiland, Louis H.</au><au>Kalser, M.</au><au>Barkin, J.</au><au>Lessner, H.</au><au>Mann‐Kaplan, R.</au><au>Redlhammer, D.</au><au>Silverman, M.</au><au>Troner, M.</au><au>Douglass, H. O.</au><au>Milliron, S.</au><au>Lokich, J.</au><au>Brooks, J.</au><au>Chaffe, J.</au><au>Like, A.</au><au>Zamcheck, N.</au><au>Ramming, K.</au><au>Bateman, J.</au><au>Spiro, H.</au><au>Livstone, E.</au><au>Knowlton, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1978-07</date><risdate>1978</risdate><volume>42</volume><issue>1</issue><spage>19</spage><epage>22</epage><pages>19-22</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Sixty‐six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin‐D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin‐D responded. The duration of responses ranged from 43–64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin‐D therapy.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>352505</pmid><doi>10.1002/1097-0142(197807)42:1&lt;19::AID-CNCR2820420103&gt;3.0.CO;2-4</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1978-07, Vol.42 (1), p.19-22
issn 0008-543X
1097-0142
language eng
recordid cdi_pubmed_primary_352505
source EZB Electronic Journals Library
subjects Adult
Aged
Bone Marrow - drug effects
Clinical Trials as Topic
Dactinomycin - adverse effects
Dactinomycin - therapeutic use
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Drug Evaluation
Female
Humans
Male
Methotrexate - adverse effects
Methotrexate - therapeutic use
Middle Aged
Pancreatic Neoplasms - drug therapy
Remission, Spontaneous
Time Factors
title Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A02%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20phase%20II%20clinical%20trial%20of%20adriamycin,%20methotrexate,%20and%20actinomycin%E2%80%90d%20in%20advanced%20measurable%20pancreatic%20carcinoma.%20A%20gastrointestinal%20tumor%20study%20group%20report&rft.jtitle=Cancer&rft.au=Schein,%20Philip%20S.&rft.date=1978-07&rft.volume=42&rft.issue=1&rft.spage=19&rft.epage=22&rft.pages=19-22&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(197807)42:1%3C19::AID-CNCR2820420103%3E3.0.CO;2-4&rft_dat=%3Cwiley_pubme%3ECNCR2820420103%3C/wiley_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p2113-df587f2ee9521878ce2eab253b06b7d654eb43c803fd7d9bf29e72906cb56eeb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/352505&rfr_iscdi=true